GKOS 250117 150.00P (GKOS250117P150000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

GKOS250117P150000

Watchlist

3.90
+2.10+116.67%

15min DelayClose Jan 10 16:00 ET

3.90High3.30Low

Intraday

5D
Daily

News

This Glaukos Insider Reduced Their Stake By 56%
Simply Wall StJan 11 09:51 ET
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
Zacks Jan 9 07:00 ET
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $157
Moomoo NewsJan 7 05:37 ET · Ratings
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $157
Moomoo NewsJan 3 06:32 ET · Ratings
Express News | Glaukos Corp : Btig Raises Target Price to $157 From $149
ReutersJan 3 06:28 ET
BTIG Sticks to Its Buy Rating for Glaukos (GKOS)
TipRanksJan 3 05:55 ET · Ratings

Comments

Moomoo AI

Jan 21, 2024 08:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 01:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 01:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

Moomoo AI

Nov 3, 2023 06:30

Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Rockhoundj

Nov 5, 2022 02:23

Let’s see if this bounces

$Glaukos (GKOS.US)$
im seeing some decent chart upside here
thoughts?